NCT04965064: Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have radiological evidence of one or more brain metastases; For patients with ER+ breast cancer, prior treatment with a CDK4/6 inhibitor and endocrine therapy is required in the metastatic setting except for those patients that received this combination of drugs in the adjuvant early stage setting and still had progression
Exclusions: Patients that do not have measurable brain metastases with at least one lesion greater than 5 mm in longest diameter; Patients who have received Xeloda (capecitabine) for the treatment of the current breast cancer in the metastatic setting; Patients with known or suspected leptomeningeal disease

Comments are closed.

Up ↑